摘要:
The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, and a peptide D having at least the amino acid sequence of SEQ ID No 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.
摘要翻译:本发明涉及新型肽组合物。 特别地,本发明涉及包含至少两种选自以下肽的肽的肽组合物:至少具有SEQ ID No1的氨基酸序列的肽A,具有至少氨基酸序列的肽B SEQ ID No45,至少具有SEQ ID No127的氨基酸序列的肽C和至少具有SEQ ID No 174的氨基酸序列的肽D.本发明的组合物特别可用于制备 针对丙型肝炎病毒的活性药物组合物。
摘要:
The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, a peptide D having at least the amino acid sequence of SEQ. ID No174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.
摘要翻译:本发明涉及新型肽组合物。 特别地,本发明涉及包含至少两种选自以下肽的肽的肽组合物:至少具有SEQ ID NO:1的氨基酸序列的肽A,肽 B至少具有SEQ ID NO:45的氨基酸序列,至少具有SEQ ID NO:127的氨基酸序列的肽C,肽D具有 至少SEQ ID NO:1的氨基酸序列。 174 N。 本发明的组合物特别可用于制备抗丙型肝炎病毒的活性药物组合物。
摘要:
The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.
摘要:
The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.
摘要:
Peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N° 1, a peptide B having at least the amino acid sequence of SEQ ID N° 45, a peptide C having at least the amino acid sequence of SEQ ID N° 127, and a peptide D having at least the amino acid sequence of SEQ ID N° 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.
摘要翻译:描述了肽组合物。 特别地,描述了包含至少两种选自以下肽的肽的肽组合物:至少具有SEQ ID NO:1的氨基酸序列的肽A,具有至少氨基酸序列的肽B SEQ ID NO:45,至少具有SEQ ID NO:127的氨基酸序列的肽C和至少具有SEQ ID NO:174的氨基酸序列的肽D.特别地, 在制备抗丙型肝炎病毒的活性药物组合物中。
摘要:
The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.
摘要:
The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.
摘要:
The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.
摘要:
Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.